###begin article-title 0
###xml 137 142 <span type="species:ncbi:9606">Human</span>
siRNA-Mediated Reduction of Inhibitor of Nuclear Factor-kappaB Kinase Prevents Tumor Necrosis Factor-alpha-Induced Insulin Resistance in Human Skeletal Muscle
###end article-title 0
###begin p 1
###xml 34 50 34 50 <email xmlns:xlink="http://www.w3.org/1999/xlink">anna.krook@ki.se</email>
Corresponding author: Anna Krook, anna.krook@ki.se
###end p 1
###begin p 2
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See  for details.
###end p 2
###begin p 3
###xml 0 10 0 10 <bold xmlns:xlink="http://www.w3.org/1999/xlink">OBJECTIVE&#8212;</bold>
OBJECTIVE-Proinflammatory cytokines contribute to systemic low-grade inflammation and insulin resistance. Tumor necrosis factor (TNF)-alpha impedes insulin signaling in insulin target tissues. We determined the role of inhibitor of nuclear factor-kappaB kinase (IKK)beta in TNF-alpha-induced impairments in insulin signaling and glucose metabolism in skeletal muscle.
###end p 3
###begin p 4
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESEARCH DESIGN AND METHODS&#8212;</bold>
###xml 232 233 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 113 118 <span type="species:ncbi:9606">human</span>
RESEARCH DESIGN AND METHODS-Small interfering RNA (siRNA) was used to silence IKKbeta gene expression in primary human skeletal muscle myotubes from nondiabetic subjects. siRNA gene silencing reduced IKKbeta protein expression 73% (P < 0.05). Myotubes were incubated in the absence or presence of insulin and/or TNF-alpha, and effects of IKKbeta silencing on insulin signaling and glucose metabolism were determined.
###end p 4
###begin p 5
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RESULTS&#8212;</bold>
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 388 389 377 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 432 433 421 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 556 559 541 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 568 569 553 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 845 848 820 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 856 859 831 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
RESULTS-Insulin increased glucose uptake 1.7-fold (P < 0.05) and glucose incorporation into glycogen 3.8-fold (P < 0.05) in myotubes from nondiabetic subjects. TNF-alpha exposure fully impaired insulin-mediated glucose uptake and metabolism. IKKbeta siRNA protected against TNF-alpha-induced impairments in glucose metabolism, since insulin-induced increases in glucose uptake (1.5-fold; P < 0.05) and glycogen synthesis (3.5-fold; P < 0.05) were restored. Conversely, TNF-alpha-induced increases in insulin receptor substrate-1 serine phosphorylation (Ser312), Jun NH2-terminal kinase phosphorylation, and extracellular signal-related kinase-1/2 mitogen-activated protein kinase (MAPK) phosphorylation were unaltered by siRNA-mediated IKKbeta reduction. siRNA-mediated IKKbeta reduction prevented TNF-alpha-induced insulin resistance on Akt Ser473 and Thr308 phosphorylation and phosphorylation of the 160-kDa Akt substrate AS160. IKKbeta silencing had no effect on cell differentiation. Finally, mRNA expression of GLUT1 or GLUT4 and protein expression of MAPK kinase kinase kinase isoform 4 (MAP4K4) was unaltered by IKKbeta siRNA.
###end p 5
###begin p 6
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CONCLUSIONS&#8212;</bold>
###xml 147 152 <span type="species:ncbi:9606">human</span>
CONCLUSIONS-IKKbeta silencing prevents TNF-alpha-induced impairments in insulin action on Akt phosphorylation and glucose uptake and metabolism in human skeletal muscle.
###end p 6
###begin p 7
Published ahead of print at  on 28 April 2008.
###end p 7
###begin p 8
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
###end p 8
###begin p 9
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 268 269 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r7">7</xref>
###xml 286 287 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r8">8</xref>
###xml 288 290 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r10">10</xref>
###xml 314 316 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r11">11</xref>
###xml 354 356 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r12">12</xref>
###xml 357 359 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r13">13</xref>
###xml 606 607 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 444 450 <span type="species:ncbi:9606">humans</span>
Subclinical inflammation plays a role in the etiology of peripheral insulin resistance in type 2 diabetes (1-6). Correlative studies in type 2 diabetic patients link excessive levels of the proinflammatory cytokine tumor necrosis factor (TNF)-alpha in adipose tissue (7), blood plasma (8-10), and skeletal muscle (11) with whole-body insulin resistance (12,13). In vivo studies provide evidence that an acute infusion of TNF-alpha into healthy humans rapidly induces skeletal muscle insulin resistance by disrupting insulin signaling to GLUT4 translocation without altering the hepatic glucose production (1). Thus, the identification and characterization of TNF-alpha-sensitive targets may provide insight into mechanism(s) for the development of peripheral insulin resistance in response to inflammatory stress.
###end p 9
###begin p 10
###xml 210 212 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 336 338 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r14">14</xref>
###xml 644 646 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r15">15</xref>
###xml 647 649 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 722 724 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r19">19</xref>
###xml 943 944 886 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 945 947 888 890 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1072 1073 1012 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 1074 1076 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1134 1136 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 937 941 <span type="species:ncbi:10090">mice</span>
TNF-alpha is principally secreted by activated macrophages in response to infection and stress. Two unique membrane receptors, TNF-alpha receptor (TNFR)1 and TNFR2, mediate the biological effects of TNF-alpha (14). The TNFR1 receptor subtype transduces TNF-alpha signaling to the transcription factor nuclear factor-kappaB (NF-kappaB) (14). TNF-alpha-induced activation of NF-kappaB is mediated by inhibitor of nuclear factor-kappaB kinase (IKK)beta, a serine kinase involved in the phosphorylation and subsequent degradation of inhibitor of nuclear factor-kappaB (IkappaB), which leads to the activation of the transcription factor NF-kappaB (15-18). IKKbeta has been implicated in the development of insulin resistance (19). High doses of salicylates target and inhibit IKKbeta to sensitize insulin signaling and reverse the associated pathogenic characteristics including hyperglycemia, hyperinsulinemia, and dyslipidemia in diabetic mice (3,20). The proposed mechanism by which salicylates sensitize insulin signaling to glucose uptake involves inhibition of IKKbeta (3,20) and enhanced insulin signaling to metabolic end points (21). Collectively, these data implicate a role for IKKbeta-mediated events in the pathogenesis of insulin resistance in obesity and type 2 diabetes.
###end p 10
###begin p 11
###xml 86 88 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 274 276 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 310 311 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 440 442 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 443 445 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r24">24</xref>
###xml 654 656 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 657 659 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 702 703 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 841 846 <span type="species:ncbi:9606">human</span>
###xml 1149 1154 <span type="species:ncbi:9606">human</span>
###xml 1251 1256 <span type="species:ncbi:9606">human</span>
TNF-alpha directly induces insulin resistance in primary human skeletal muscle cells (22). TNF-alpha-mediated insulin resistance can be rescued via small interfering RNA (siRNA)-mediated silencing of mitogen-activated protein kinase kinase kinase kinase isoform 4 (MAP4K4) (22), an upstream regulator of Jun NH2-terminal kinase (JNK) and extracellular signal-related kinase (ERK)1/2 (p42/44 mitogen-activated protein kinase [MAPK]) kinase (22-24). In addition to mediating insulin resistance through the activation of JNK, TNF-alpha exerts negative effects on insulin signaling through the serine/threonine kinase IKKbeta in cultured immortalized cells (25,26) and in animal models of type 2 diabetes (3). Here, we test the hypothesis that IKKbeta is an intermediate kinase for TNF-alpha action on insulin-mediated glucose uptake in primary human skeletal muscle cells. We provide evidence that TNF-alpha-induced insulin resistance on signal transduction at the level of Akt is prevented by siRNA-mediated silencing of IKKbeta. We also show that the TNF-alpha-induced impairments on insulin-mediated glucose uptake and glycogen synthesis in primary human myotubes are prevented by IKKbeta inhibition. Thus, strategies to inhibit IKKbeta expression in human skeletal muscle may prevent insulin resistance associated with inflammatory stress.
###end p 11
###begin title 12
RESEARCH DESIGN AND METHODS
###end title 12
###begin p 13
###xml 229 230 225 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Skeletal muscle biopsies were obtained with informed consent from nondiabetic individuals (seven male and two female) scheduled for abdominal surgery. The mean age and BMI of the subjects were 57 +/- 2 years and 25.8 +/- 0.9 kg/m2, respectively. None of the subjects had any known metabolic disorders, and all presented with normal fasting plasma glucose values (5.5 +/- 0.3 mmol/l). The protocols in this study were approved by the ethics committee at Karolinska Institutet.
###end p 13
###begin p 14
###xml 60 66 <span type="species:ncbi:9913">bovine</span>
###xml 177 182 <span type="species:ncbi:9606">human</span>
DMEM (Dulbecco's modified Eagle's medium), DMEM F-12, fetal bovine serum, penicillin, streptomycin, and Fungizone were obtained from Invitrogen (Stockholm, Sweden). Recombinant human TNF-alpha and general laboratory reagents were obtained from Sigma (St. Louis, MO), PD98059 was obtained from Calbiochem (La Jolla, CA), and radioactive reagents were purchased from Amersham (Uppsala, Sweden).
###end p 14
###begin title 15
Cell culture and siRNA transfection.
###end title 15
###begin p 16
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r27">27</xref>
###xml 366 368 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r28">28</xref>
Satellite cells were isolated from muscle biopsies and cultured as previously described (27). IKKbeta-specific siRNA oligos were purchased from Ambion (Austin, TX). Myotubes transfected with oligos against a scrambled sequence (scrambled siRNA) were used as a control. Myotubes were transfected using Lipofectamine 2000 (Invitrogen, Sweden) as previously described (28).
###end p 16
###begin title 17
Western blot analysis.
###end title 17
###begin p 18
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 546 549 526 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 560 563 540 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 596 599 576 579 <sup xmlns:xlink="http://www.w3.org/1999/xlink">202</sup>
###xml 603 606 583 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink">204</sup>
###xml 648 655 628 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink">183/185</sup>
###xml 699 700 676 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 823 826 800 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
Cells were harvested and protein concentration was determined using the Pierce method. After protein determination, aliquots of lysates were mixed with 4x Laemmli-sample buffer, and proteins were separated by SDS-PAGE. Proteins were visualized by enhanced chemiluminescence and quantified by densitometry (29). TNF-alpha-induced degradation of IkappaBalpha was analyzed in lysates by immunoblot analysis with anti-IkappaBalpha (Cell Signaling, Beverly, MA). Signaling parameters were investigated using phosphospecific antibodies against Akt (Ser473), Akt (Thr308), ERK1/2, p42/44 MAPK kinase Thr202/Tyr204, stress-activated protein kinase/JNK (Thr183/185), glycogen synthase kinase (GSK)-3beta (Ser9), and phospho-Akt Substrate (RXRXXS/T) (Cell Signaling). Antibodies against phospho-insulin receptor substrate (IRS)-1 Ser312 and total IRS-1 were purchased from Upstate (Charlottesville, VA). Antibodies against total IKKbeta, Akt, and ERK were from Cell Signaling. Mitogen-activated protein kinase kinase (MEK) isoform 4 (MAP2K4) and MAP4K4 antibodies were obtained from Abgent (San Diego, CA), glyceraldehyde-3-phosphate dehydrogenase from Santa Cruz Biotechnology (Santa Cruz, CA), and Desmin from Abcam (Cambridge, U.K.).
###end p 18
###begin title 19
Glucose uptake and metabolism.
###end title 19
###begin p 20
###xml 295 297 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r29">29</xref>
###xml 422 424 418 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 430 432 426 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;1</sup>
###xml 23 28 <span type="species:ncbi:9606">human</span>
Differentiated primary human muscle myotubes were exposed to saline or TNF-alpha (20 ng/ml) for 2 h. Thereafter, myotubes were incubated in the absence or presence of insulin (120 nmol/l), and 2-deoxyglucose uptake or glucose incorporation into glycogen was determined, as previously described (29). Total protein concentration was assessed using the Bradford method (Bio-Rad, Richmond, CA). Data are reported as nmol . mg-1 . min-1.
###end p 20
###begin title 21
Statistics.
###end title 21
###begin p 22
###xml 90 91 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Data are presented as means +/- SEM. Statistical differences were determined by Student's t test or ANOVA using Fisher's least significant differences test for post hoc determination.
###end p 22
###begin title 23
RESULTS
###end title 23
###begin title 24
IKKbeta silencing in myotubes.
###end title 24
###begin p 25
###xml 370 371 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 364 371 348 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 435 436 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 429 436 410 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>A</italic></xref>
###xml 439 440 420 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 477 478 458 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 658 659 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 652 659 618 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f1" ref-type="fig">Fig. 1<italic>B</italic></xref>
###xml 941 942 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 935 942 869 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>A</italic></xref>
###xml 1148 1149 1079 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1142 1149 1073 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f2" ref-type="fig">Fig. 2<italic>B</italic></xref>
###xml 102 107 <span type="species:ncbi:9606">human</span>
The effect of IKKbeta gene silencing on IKKbeta protein expression was determined in primary cultured human myotubes. Two days after induction of the myotube differentiation program, cells were transfected with siRNA against IKKbeta. Expression of IKKbeta was unaltered in cells exposed to a scrambled siRNA sequence or following 2 h of incubation with TNF-alpha (Fig. 1A). siRNA against IKKbeta reduced protein expression 73%, (Fig. 1A) (P < 0.05) and mRNA expression by 55% (P < 0.01) (data not shown) compared with cells transfected with scrambled siRNA. Following TNF-alpha exposure (2 h, 20 ng/ml), protein content of Ikappabetaalpha was reduced (Fig. 1B), indicating that Ikappabetaalpha was targeted for degradation after cytokine exposure. siRNA against IKKbeta increased the basal expression of Ikappabetaalpha and blunted the TNF-alpha-mediated reduction. Myotube growth and morphology was unaltered after IKKbeta silencing (Fig. 2A). Expression of the myogenic protein desmin following 6 days of differentiation (4 days after transfection) was unaltered between myotubes treated with siRNA against a scrambled sequence or IKKbeta (Fig. 2B).
###end p 25
###begin title 26
Effect of IKKbeta silencing on glucose uptake and metabolism.
###end title 26
###begin p 27
###xml 150 152 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 307 308 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 301 308 290 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>A</italic></xref>
###xml 349 350 338 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 343 350 332 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f3" ref-type="fig">Fig. 3<italic>B</italic></xref>
###xml 568 569 553 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 611 612 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 795 796 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 836 837 813 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 127 132 <span type="species:ncbi:9606">human</span>
We have reported that an acute TNF-alpha exposure impairs insulin-stimulated glucose uptake and glycogen synthesis in cultured human skeletal muscle (22). Here, we determined whether TNF-alpha-induced insulin resistance is prevented by IKKbeta silencing. Four days after transfection, glucose uptake (Fig. 3A) and incorporation into glycogen (Fig. 3B) was assessed under basal and insulin-stimulated conditions in the presence or absence of TNF-alpha. In control cells or cells transfected with scrambled siRNA, insulin (120 nmol/l) increased glucose uptake 1.7-fold (P < 0.05) and glycogen synthesis 3.8-fold (P < 0.05). Basal glucose transport and incorporation to glycogen was unaltered in cells exposed to TNF-alpha. However, TNF-alpha pretreatment reduced insulin action on glucose uptake (P < 0.05) and incorporation to glycogen (P < 0.05). Silencing of IKKbeta had no effect on either basal or insulin-stimulated glucose metabolism. Importantly, siRNA-mediated silencing of IKKbeta prevented the inhibitory effect of TNF-alpha on insulin-mediated glucose metabolism.
###end p 27
###begin title 28
Effect of IKKbeta silencing on Akt phosphorylation.
###end title 28
###begin p 29
###xml 25 28 25 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 36 39 36 39 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 102 115 102 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>A</italic> and <italic>B</italic></xref>
###xml 255 258 251 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 266 269 262 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 287 288 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 385 388 378 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 395 398 388 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 563 564 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 557 564 542 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f4" ref-type="fig">Fig. 4<italic>C</italic></xref>
###xml 79 84 <span type="species:ncbi:9606">human</span>
Insulin increased Akt Ser473 and Thr308 phosphorylation in primary cultures of human skeletal muscle (Fig. 4A and B, respectively). Insulin action on Akt was unaltered in cells transfected with scrambled siRNA. TNF-alpha impaired insulin action on Akt Ser473 and Thr308 phosphorylation (P < 0.05). IKKbeta silencing had no effect on basal (data not shown) or insulin-stimulated Akt Ser473 or Thr308 phosphorylation but prevented the TNF-alpha-induced impairment. Protein expression of Akt was unaltered in response to insulin, TNF-alpha, or gene silencing (Fig. 4C).
###end p 29
###begin title 30
Effect of IKKbeta silencing on GSK3beta and AS160 phosphorylation.
###end title 30
###begin p 31
###xml 186 187 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 195 196 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 189 196 180 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>A</italic></xref>
###xml 215 216 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 209 216 200 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f5" ref-type="fig">Fig. 5<italic>B</italic></xref>
###xml 380 381 364 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 561 562 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 241 246 <span type="species:ncbi:9606">human</span>
To further evaluate the effect of IKKbeta on insulin signaling, phosphorylation of the Akt substrates GSK3beta and AS160 was determined. Insulin increased phosphorylation of GSK3beta Ser9 (Fig. 5A) and AS160 (Fig. 5B) in primary cultures of human skeletal muscle. These responses were unaltered in cells transfected with scrambled siRNA. TNF-alpha treatment increased GSK3beta Ser9 phosphorylation to the same extent as insulin but had no effect on insulin-mediated phosphorylation. Silencing of IKKbeta had no effect on basal or insulin-stimulated GSK3beta Ser9 and prevented the TNF-alpha-induced increase in GSK3beta phosphorylation. TNF-alpha treatment prevented the insulin-mediated increase in AS160 phosphorylation, and silencing of IKKbeta restored this insulin effect.
###end p 31
###begin title 32
Effect of IKKbeta silencing on ERK 1/2 MAPK phosphorylation.
###end title 32
###begin p 33
###xml 48 49 48 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 110 111 110 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 104 111 104 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>A</italic></xref>
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 269 270 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 894 895 867 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 888 895 861 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f6" ref-type="fig">Fig. 6<italic>D</italic></xref>
###xml 81 86 <span type="species:ncbi:9606">human</span>
Insulin increased ERK 1/2 MAPK phosphorylation (P < 0.05) in primary cultures of human skeletal muscle (Fig. 6A-C). Insulin action on ERK 1/2 MAPK was unaltered in cells transfected with scrambled siRNA. TNF-alpha exposure increased basal ERK 1/2 MAPK phosphorylation (P < 0.05), although to a lesser extent than observed in response to insulin. TNF-alpha exposure did not modify insulin action on ERK 1/2 MAPK phosphorylation. IKKbeta silencing had no effect on ERK 1/2 MAPK phosphorylation either in the absence or presence of insulin and/or TNF-alpha. Total ERK expression was unaltered in response to TNF-alpha exposure or siRNA gene silencing. To further explore the role of ERK in the mediation of TNF-alpha-induced impairments in insulin-mediated glucose metabolism, we determined the effect of the MEK inhibitor PD98059 on glycogen synthesis in response to insulin and TNF-alpha (Fig. 6D). Exposure of primary cultures to PD98059 reduced insulin and TNF-alpha-mediated ERK1/2 phosphorylation (data not shown). However, this inhibitor had no effect on glycogen synthesis in response to insulin or TNF-alpha exposure.
###end p 33
###begin title 34
Effect of IKKbeta silencing on JNK phosphorylation.
###end title 34
###begin p 35
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 107 113 107 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f7" ref-type="fig">Fig. 7</xref>
###xml 84 89 <span type="species:ncbi:9606">human</span>
Insulin increased p54 and p46 JNK phosphorylation (P < 0.05) in primary cultures of human skeletal muscle (Fig. 7). Insulin action on p54 and p46 JNK was unaltered in cells transfected with scrambled siRNA. Similar to results noted for ERK1/2 MAPK, TNF-alpha exposure increased basal p54 and p46 JNK phosphorylation, and IKKbeta silencing had no effect on JNK phosphorylation either in the absence or presence of insulin and/or TNF-alpha.
###end p 35
###begin title 36
###xml 56 59 53 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
Effect of IKKbeta silencing on IRS-1 gel mobility or Ser312 phosphorylation.
###end title 36
###begin p 37
###xml 79 82 75 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 164 167 153 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 252 255 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 279 280 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 273 280 258 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f8" ref-type="fig">Fig. 8<italic>A</italic></xref>
###xml 585 586 563 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 579 586 557 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="f8" ref-type="fig">Fig. 8<italic>B</italic></xref>
###xml 195 200 <span type="species:ncbi:9606">human</span>
TNF-alpha exposure is associated with increased phosphorylation of IRS-1 on Ser312. Thus, we determined whether IKKbeta plays a role in TNF-alpha-mediated IRS-1 Ser312 phosphorylation in primary human myotubes. Insulin and TNF-alpha increased IRS-1 Ser312 phosphorylation (Fig. 8A), and this response was unaltered in cells transfected with siRNA against either a scrambled sequence or IKKbeta. To evaluate the total phosphorylation status of IRS-1, a gel mobility shift assay was performed. Insulin and TNF-alpha induced an upward mobility shift in IRS-1 migration in SDS-PAGE (Fig. 8B), indicating increased phosphorylation. The effect of insulin on IRS-1 mobility was unaltered in cells transfected with scrambled siRNA. IKKbeta silencing had no effect on the mobility shift of IRS-1 in response to either insulin or TNF-alpha exposure. Thus, IKKbeta does not appear to mediate TNF-alpha-induced phosphorylation events on IRS-1.
###end p 37
###begin title 38
Effect of IKKbeta silencing on mRNA and protein expression.
###end title 38
###begin p 39
###xml 270 272 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
Gene silencing of IKKbeta did not alter either GLUT1 or GLUT4 mRNA (105 +/- 31 or 87 +/- 12%, respectively, as compared with cells transfected with a scrambled sequence). Because we have recently reported that MAP4K4 siRNA prevents TNF-alpha-induced insulin resistance (22), protein expression of MAP4K4 and the upstream kinase MAP2K4 was also assessed in cells transfected with siRNA against a scrambled sequence or IKKbeta. Protein content of either MAP4K4 or MAP2K4 was unaltered in myotubes transfected with scrambled or IKKbeta siRNA (data not shown).
###end p 39
###begin title 40
DISCUSSION
###end title 40
###begin p 41
###xml 167 169 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 170 172 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r18">18</xref>
###xml 173 175 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r30">30</xref>
###xml 176 178 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 342 344 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 521 529 484 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKK&#945;</italic>
###xml 529 530 488 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 530 531 489 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">/</sup>
###xml 531 532 490 491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 559 561 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r31">31</xref>
###xml 593 600 549 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKK&#946;</italic>
###xml 600 603 553 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;/&#8722;</sup>
###xml 633 635 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r32">32</xref>
###xml 813 815 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r17">17</xref>
###xml 816 818 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r33">33</xref>
###xml 932 933 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 934 935 857 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 936 938 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 939 941 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 942 944 865 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 945 947 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 1119 1120 1039 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r2">2</xref>
###xml 1121 1122 1041 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 1123 1125 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 1126 1128 1046 1048 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 618 623 <span type="species:ncbi:10090">mouse</span>
###xml 1403 1408 <span type="species:ncbi:9606">human</span>
IKKbeta is a core component of the oligomeric IKK complex, which consists of two catalytic subunits, IKKalpha and IKKbeta, and a regulatory subunit IKKgamma, or NEMO (16,18,30,31). The two catalytic subunits share approximately50% amino acid sequence homology, whereas the regulatory subunit does not contain a recognizable catalytic domain (21). Despite the overall sequence identity between IKKalpha and IKKbeta, these subunits have specialized roles as mediators of cellular stress. For example, deletion of IKKalpha (IKKalpha-/-) causes limb deformities (31), whereas deletion of IKKbeta (IKKbeta-/-) is lethal in mouse embryos (32). Of the two catalytic subunits, IKKbeta is considered to be the main regulator of NF-kappaB function because of its higher activity (approximately30-fold) toward IkappaBalpha (17,33). Recent evidence underscores a central role of IKKbeta in insulin sensitivity and type 2 diabetes pathogenesis (2,3,20,21,34,35). High doses of salicylates, which repress IKKbeta activity, reverse hyperglycemia, hyperinsulinemia, and dyslipidemia in obese rodents by increasing insulin sensitivity (2,3,20,21). Consequently, we determined the role of IKKbeta in insulin action on glucose uptake using siRNA-mediated gene silencing. We provide evidence that IKKbeta plays a role in TNF-alpha-induced impairments in insulin action on Akt signaling and glucose uptake and metabolism in human skeletal muscle.
###end p 41
###begin p 42
###xml 132 134 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r36">36</xref>
###xml 135 137 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 225 227 209 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 235 237 219 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">36</sup>
###xml 358 360 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r16">16</xref>
###xml 584 586 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r38">38</xref>
###xml 889 891 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 1384 1386 1268 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r37">37</xref>
###xml 1387 1389 1271 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r39">39</xref>
###xml 1390 1392 1274 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r40">40</xref>
TNF-alpha has a biphasic response to NF-kappaB, which is required for cytokine-induced skeletal muscle damage and wasting/cachexia (36,37). Cytokines activate the IKK complex, leading to phosphorylation of IkappaBalpha on Ser32 and Ser36. Phosphorylation of these residues causes polyubiquitination and subsequent degradation of IkappaBalpha by proteosomes (16). The breakdown of IkappaBalpha leads to the release and nuclear translocation of NF-kappaB, where it binds to target genes and drives the expression of cytokines, including TNF-alpha, interleukin-6, and interleukin-1beta (38). Here, we report that a 2-h TNF-alpha exposure of cultured myotubes decreased Ikappabetaalpha protein content, indicating that Ikappabetaalpha is targeted for degradation after cytokine exposure. This finding is consistent with the first transient phase of TNF-alpha-mediated activation of NF-kappaB (37). The siRNA-mediated reduction of IKKbeta prevented the TNF-alpha effect on Ikappabetaalpha degradation. Skeletal muscle wasting/cachexia, due to accelerated protein degradation through ubiquitin-dependent proteolysis, occurs in a manner analogous to IKKbeta-mediated degradation of IkappaBalpha. Genetic inhibition of the IKKbeta/NF-kappaB/MuRF1 pathway or through pharmacological therapeutics, such as salicylates to inhibit IKKbeta activity, rescues the skeletal muscle-wasting phenotype (37,39,40). In the current study, skeletal muscle morphology was not altered by either TNF-alpha exposure or siRNA-mediated gene silencing of IKKbeta. However, our experiments were limited to a short-term (first phase) TNF-alpha exposure, and we did not directly test whether IKKbeta siRNA would modify culture growth in the presence of a long-term (second phase) TNF-alpha exposure.
###end p 42
###begin p 43
###xml 89 90 85 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r1">1</xref>
###xml 105 107 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r41">41</xref>
###xml 108 110 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r42">42</xref>
###xml 147 149 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 457 458 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r5">5</xref>
###xml 459 460 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r6">6</xref>
###xml 461 463 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r35">35</xref>
###xml 568 570 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 571 573 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 669 670 648 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 671 673 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r20">20</xref>
###xml 674 676 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r21">21</xref>
###xml 737 739 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r43">43</xref>
###xml 937 939 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r44">44</xref>
###xml 81 87 <span type="species:ncbi:9606">humans</span>
###xml 259 267 <span type="species:ncbi:9606">patients</span>
###xml 815 821 <span type="species:ncbi:9606">humans</span>
TNF-alpha directly induces skeletal muscle insulin resistance in vivo in healthy humans (1) and rodents (41,42) and in vitro in cultured myotubes (22). Although the role of TNF-alpha in the development of skeletal muscle insulin resistance in type 2 diabetic patients remains unresolved, current evidence suggests that IKKbeta may be an intermediate kinase through which TNF-alpha and other inflammatory processes induce skeletal muscle insulin resistance (5,6,35). IKKbeta activation has been closely linked to the development and pathogenesis of insulin resistance (20,21). Pharmacological inhibition of IKKbeta activity improves insulin-mediated glucose metabolism (3,20,21), even in insulin-resistant obese, nondiabetic individuals (43). Increased expression of IKKbeta has been noted in omental fat from obese humans, potentially contributing to differential roles of omental and subcutaneous fat in the pathophysiology of obesity (44).
###end p 43
###begin p 44
###xml 253 255 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r45">45</xref>
###xml 278 281 269 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 335 340 326 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob/ob</italic>
###xml 419 420 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r3">3</xref>
###xml 538 541 523 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/&#8722;</sup>
###xml 646 648 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r46">46</xref>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 282 286 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 435 439 <span type="species:ncbi:10090">mice</span>
Studies linking IKKbeta and skeletal muscle insulin resistance in rodents have yielded conflicting results. Pharmacological IKKbeta inhibition ameliorated insulin resistance and upregulated plasma levels of adiponectin in KKAy mice fed a high-fat diet (45). Heterozygous IKKbeta+/- mice fed a high-fat diet or intergressed on an obese ob/ob mice background were protected against the development of insulin resistance (3). Conversely, mice with either skeletal muscle-specific IKKbeta knockout or a separate cohort of heterozygous IKKbeta+/- were not protected against gold thioglucose-induced obesity or dietary-induced metabolic abnormalities (46). The reason for the differences noted between these animal models is unknown, but the differences could be strain specific or related to undefined experimental differences.
###end p 44
###begin p 45
###xml 227 229 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r47">47</xref>
###xml 455 458 441 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 463 466 449 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 877 880 845 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 1028 1031 993 996 <sup xmlns:xlink="http://www.w3.org/1999/xlink">307</sup>
###xml 1062 1065 1027 1030 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 1148 1150 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r25">25</xref>
###xml 1151 1153 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r26">26</xref>
###xml 1154 1156 1119 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r48">48</xref>
###xml 1047 1052 <span type="species:ncbi:9606">human</span>
TNF-alpha exposure leads to activation of two separate transcription factor-signaling pathways, namely the IKKbeta and JNK pathways, which are linked to proinflammatory responses associated with obesity and insulin resistance (47). Here, we show that siRNA-mediated gene silencing of IKKbeta prevented TNF-alpha-induced insulin resistance on glucose uptake and metabolism in cultured myotubes, with a concomitant increase in phosphorylation of Akt (at Ser473, Thr308), and AS160. Inhibition of ERK signaling using pharmacological inhibitor PD98059 did not alter TNF-alpha-mediated reduction in insulin-stimulated glycogen synthesis. Furthermore, the TNF-alpha-mediated activation of ERK and JNK was unaffected by the siRNA-mediated reduction of IKKbeta. Additionally, the siRNA-mediated reduction of IKKbeta did not prevent TNF-alpha-induced IRS-1 serine phosphorylation on Ser312 or the IRS-1 mobility shift as determined by SDS-PAGE. This is in contrast to some reports indicating that inhibition of IKKbeta prevents IRS-1 Ser307 (equivalent to human IRS-1 Ser312) phosphorylation in cultured HEPG2, 3T3-L1 adipocytes, or embryonic kidney cells (25,26,48) but is consistent with other observations that IKKbeta is disassociated from IRS-1 phosphorylation (Steven E. Shoelson, Joslin Diabetes Center, Boston, MA, personal communication). Our results indicate that the TNF-alpha effect on IRS-1 serine phosphorylation is primarily mediated via parallel IKKbeta independent pathways, such as JNK.
###end p 45
###begin p 46
IKKbeta silencing fully restored the TNF-alpha-mediated reduction of insulin-stimulated glucose metabolism, despite modest impairments in insulin signaling at the level of Akt. However, TNF-alpha exposure was associated with a profound impairment in insulin-stimulated AS160 phosphorylation, which was restored following IKKbeta silencing. Since AS160 is a critical step in the processes involved from insulin signaling to glucose transport, this may explain the enhanced glucose metabolism in IKKbeta-depleted myotubes. Our results may also indicate that a relatively small pool of total Akt is critical for signaling to AS160, and this pool may be highly sensitive to TNF-alpha, possibly due to cellular localization.
###end p 46
###begin p 47
###xml 205 207 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r49">49</xref>
###xml 428 430 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r50">50</xref>
###xml 631 632 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 736 739 702 705 <sup xmlns:xlink="http://www.w3.org/1999/xlink">641</sup>
###xml 849 851 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r51">51</xref>
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 176 181 <span type="species:ncbi:10090">mouse</span>
In primary cultures of human muscle, TNF-alpha exposure enhanced phosphorylation of GSK3beta. This finding is consistent with a finding of a previous study in HEK293 cells and mouse embryonic fibroblasts (49), where TNF-alpha-mediated activation of ERK was partly dependent on GSK3beta phosphorylation. Conversely, TNF-alpha exposure has also been shown to prevent insulin-stimulated phosphorylation of GSK3beta in HEPG2 cells (50). Here, we report that IKKbeta silencing prevents the TNF-alpha-mediated increase in GSK3beta phosphorylation; however, the functional consequence requires further investigation. Although GSK3beta Ser9 phosphorylation has been linked to a reduction in the constitutive ability of GSK3 to phosphorylate Ser641 of glycogen synthase, it does not completely abolish the ability of GSK3 to phosphorylate glycogen synthase (51). Thus, further studies are warranted to establish whether GSK3 activity is modulated.
###end p 47
###begin p 48
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r23">23</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r34">34</xref>
###xml 564 566 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="r22">22</xref>
###xml 947 950 920 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 532 537 <span type="species:ncbi:9606">human</span>
MAP4K4 is a member of the NCK interacting kinase family (23). NCK interacting kinase family kinases are potent activators of the IKK complex and activators of ERK and JNK (34), which suggests that MAP4K4 is likely to be an upstream regulator of IKKbeta. Here, we show that siRNA-mediated silencing of IKKbeta had no effect on expression of MAP4K4, excluding a negative feedback on this upstream kinase. We have previously reported that the siRNA-mediated reduction of MAP4K4 rescues TNF-alpha-mediated insulin resistance in primary human skeletal muscle cultures (22), consistent with our present findings for IKKbeta. Although a reduction of either MAP4K4 or IKKbeta prevents the effect of TNF-alpha on insulin-mediated glucose uptake and metabolism, the reduction of MAP4K4 also prevented IRS-1 serine phosphorylation and signaling to ERK 1/2 and JNK. In contrast, siRNA silencing of IKKbeta did not alter TNF-alpha signaling to either IRS-1 Ser312, JNK, or ERK phosphorylation. These results are consistent with the hypothesis that downstream signals from MAP4K4 diverge toward an ERK/JNK pathway that mediates effects on IRS-1 serine phosphorylation and an IKKbeta pathway that mediates effects on glucose uptake and metabolism.
###end p 48
###begin p 49
###xml 170 175 <span type="species:ncbi:9606">human</span>
In summary, targeted deletion of IKKbeta using siRNA prevents TNF-alpha-mediated insulin resistance on Akt and AS160 phosphorylation and glucose uptake and metabolism in human skeletal muscle. These results underscore IKKbeta as a potential therapeutic target to prevent peripheral insulin resistance.
###end p 49
###begin p 50
This study was supported by grants from the Swedish Research Council, the Swedish Medical Association, the Novo-Nordisk Foundation, the Swedish Diabetes Association, the Swedish Animal Welfare Agency, the Hedlund Foundation, the Strategic Research Foundation, and the Commission of the European Communities (contract no. LSHM-CT-2004-005272 EXGENESIS, contract no. LSHM-CT-2004-512013 EUGENEHEART, and contract no. LSHM-CT-2004-512013 EUGENE2).
###end p 50
###begin title 51
REFERENCES
###end title 51
###begin p 52
###xml 48 49 37 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 176 181 158 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 181 184 163 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;3</italic>
###xml 244 249 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes</italic>
###xml 249 256 228 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">4 and 5</italic>
###xml 364 365 343 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 463 464 429 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 519 520 485 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Protein expression of IKKbeta and IkappaBalpha. A: Protein expression of IKKbeta was unaltered in cells exposed to a scrambled siRNA sequence, a 2-h incubation with TNF-alpha (lanes1-3). siRNA against IKKbeta reduced protein expression by 73% (lanes4 and 5). Glyceraldehyde-3-phosphate dehydrogenase (GADPH) expression was determined to control for equal loading. B: IkappaBalpha was measured after siRNA-mediated depletion of IKKbeta. Results are means +/- SE. *P < 0.05 vs. transfected scrambled siRNA (Scr) control (n = 4).
###end p 52
###begin p 53
###xml 16 17 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 321 322 318 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 47 52 <span type="species:ncbi:9606">human</span>
Myotube growth. A: Morphological appearance of human skeletal muscle myotube formation after introduction of scrambled siRNA or siRNA against IKKbeta. Photomicrographs are shown at 10x magnification for myotubes at day 6 of differentiation (4 days after introduction of siRNA). Results are from two separate experiments. B: Representative immunoblot showing the differentiation marker desmin.
###end p 53
###begin p 54
###xml 104 105 101 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 131 132 128 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 319 320 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 362 363 321 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 429 430 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Effect of siRNA-mediated silencing of IKKbeta on glucose uptake and glycogen synthesis. Glucose uptake (A) and glycogen synthesis (B) were measured in differentiated primary skeletal muscle myotubes under basal conditions (square) and after insulin stimulation (blacksquare, square, filled). Results are means +/- SE. *P < 0.05 vs. respective basal cells. daggerP < 0.05 vs. TNF-alpha-and insulin-stimulated untransfected cells (n = 4).
###end p 54
###begin p 55
###xml 7 10 7 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 18 21 18 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 80 83 80 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink">473</sup>
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 99 102 99 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">308</sup>
###xml 104 105 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 161 162 157 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 237 238 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 286 287 275 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 341 342 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Akt Ser473 and Thr308 phosphorylation. Representative immunoblot showing Akt Ser473 (A) and Akt Thr308 (B) phosphorylation in response to insulin and TNF-alpha. C: Total Akt protein expression. Graphs are summarized data (mean +/- SE). *P < 0.05% vs. untransfected control cells. daggerP < 0.05 vs. TNF-alpha-stimulated untransfected cells (n = 9).
###end p 55
###begin p 56
###xml 84 85 78 79 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 87 88 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 115 116 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 306 307 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 343 344 295 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 399 400 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 437 438 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 451 452 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
GSK-3beta and AS160 phosphorylation. Representative immunoblot showing pGSK3beta Ser9 (A) and Akt substrate AS160 (B) phosphorylation in response to insulin or TNF-alpha under basal conditions (square) and after insulin stimulation (blacksquare, square, filled). Graphs are summarized data (mean +/- SE). *P < 0.05 vs. respective basal. daggerP < 0.05 vs. TNF-alpha-stimulated untransfected cells. #P < 0.05 vs. control basal (GSK3beta, n = 3; AS160, n = 4).
###end p 56
###begin p 57
###xml 78 79 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 139 140 136 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 174 175 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 298 299 264 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 306 307 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 510 511 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 542 543 505 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Effect of siRNA-mediated silencing of IKKbeta on ERK1/2 MAPK phosphorylation. A: Representative immunoblot of ERK1/2 MAPK phosphorylation. B: Total ERK-2 protein expression. C: Summarized results for ERK1/2 MAPK under basal (square) or insulin-stimulated (blacksquare, square, filled) conditions. (n = 5). D: Glycogen synthesis was measured in differentiated primary skeletal muscle myotubes following 1 h of exposure to 50 mumol/l PD98059. Results are means +/- SE from experiment carried out in triplicate. *P < 0.05 vs. respective basal. #P < 0.05 vs. control basal.
###end p 57
###begin p 58
###xml 70 71 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 136 137 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 305 306 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 337 338 301 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 365 366 329 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Effect of siRNA-mediated silencing of IKKbeta on JNK phosphorylation. A: Representative immunoblot showing p54/p46 JNK phosphorylation. B: Summarized results for p54 and p46 JNK phosphorylation under basal (square) or insulin-stimulated (blacksquare, square, filled) conditions. Results are mean +/- SE. *P < 0.05 vs. respective basal. #P < 0.05 vs. control basal (n = 3).
###end p 58
###begin p 59
###xml 58 61 55 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 142 143 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 157 160 154 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 178 179 175 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 191 194 188 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink">312</sup>
###xml 416 417 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 420 421 384 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
Effect of siRNA-mediated silencing of IKKbeta on IRS-1 Ser312 phosphorylation. Representative immunoblot showing IRS-1 migration on SDS-PAGE (A) or IRS-1 Ser312 phosphorylation (B). IRS-1 Ser312 phosphorylation results under basal (square) and insulin-stimulated (blacksquare, square, filled) conditions are reported as means +/- SE percent relative to basal untransfected controls. Arrow highlights mobility shift (A) (n = 4).
###end p 59

